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Purpose: To determine how many endovascular aneurysm sealing (EVAS) procedures with/without off-label use of chimneys (ChEVAS) could have been done in a cohort of patients who had fenestrated endovascular aneurysm repair (FEVAR).
Methods: Sixty patients (median age 76.3 years; 54 men) who underwent FEVAR in our institution between 2013 and 2015 were selected for the study. The median aneurysm diameter was 62.0 mm (interquartile range 59.3, 69.0). Preoperative computed tomography angiograms (CTA) were anonymized and sent to 2 physicians with experience of over 40 ChEVAS interventions. These ChEVAS planners were blinded to the study purpose and asked to agree upon an EVAS/ChEVAS plan. The primary outcome was the percentage of the FEVAR patients in whom an EVAS/ChEVAS was technically possible. The secondary outcomes were a comparison of seal zones, number of target vessels, and device cost.
Results: An EVAS-based intervention would have been technically possible in 56 (93.3%) of the FEVAR patients. The median proximal aortic seal zone was significantly more distal in the EVAS/ChEVAS procedures vs the FEVAR cases (zone 8 vs zone 7, p<0.001) and fewer target vessels were involved (median 2 vs 3, p<0.001). The cost of the EVAS/ChEVAS device was 66% of the FEVAR device. Planners would not currently advocate an EVAS-based intervention in 43 (76.8%) of these 56 patients due to concerns regarding the risk of migration associated with the lumen thrombus ratios observed. 
Conclusion: EVAS is technically feasible in the majority of patients undergoing FEVAR in our institution but currently advocated in only 23.2%. The seal zone was more distal, fewer target vessels were involved, and the device cost was lower in the planned EVAS/ChEVAS interventions. 
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Fenestrated endovascular aneurysm repair (FEVAR) evolved to treat aortic aneurysms that involved the visceral aorta. In the nearly 20 years since its debut,1 FEVAR has demonstrated significantly lower perioperative mortality than open surgical repair of these “complex” aneurysms, ADDIN EN.CITE 2,3 which comprise 28.6% of all elective EVARs in the UK.3 Currently, FEVAR is the most common treatment for complex aneurysms in this country.3
	FEVAR is typically utilized to repair juxtarenal aneurysms,4 which oftentimes have an insufficient infrarenal proximal neck or poor seal zone morphology (eg, barrel or conical necks) for standard EVAR. Over the years, FEVAR stent-graft designs have progressively involved more proximal seal zones5 as the complexity of cases has increased and more durable results from sealing more proximally have been sought.6 The value of this changing practice is still to be fully defined but may be associated with increased perioperative mortality ADDIN EN.CITE 5,7 and possibly increased risk of spinal cord ischemia, mesenteric ischemia, and renal failure in the more complex FEVAR stent-grafts.
	Chimney endovascular aneurysm repair (ChEVAR) is an established alternative to FEVAR.8 ChEVAR involves the placement of covered balloon-expandable stents into the renovisceral vessels up to the desired seal zone. An oversized standard infrarenal stent-graft is then deployed and balloon molded around these stents to create a seal. ChEVAR has the advantage of not requiring patient-specific devices and therefore has no manufacture delay as FEVAR does. The ChEVAR technique has received Conformité Européenne marking when performed within the instructions for use (IFU) of the Endurant II stent-graft (Medtronic Inc, Dublin, Ireland) with up to 2 balloon-expandable covered chimney stents for the renal arteries.9 This approval was based on the results of the standardized device used within the PROTAGORAS study. ADDIN EN.CITE 10 The concern with ChEVAR is that the gutters between the visceral stents and aortic stent-graft may lead to proximal endoleaks that could reduce durability. ADDIN EN.CITE 11 The PERICLES Registry demonstrated a type Ia endoleak rate of 7.9% in over 500 ChEVAR procedures. ADDIN EN.CITE 12
	Endovascular aneurysm sealing (EVAS) is a well described technique to treat aortic aneurysms using the Nellix EVAS system (Endologix Inc, Irvine, CA, USA).13,14 Nellix consists of 2 balloon-expandable chromium-cobalt stents surrounded by polytetrafluoroethylene endobags that are filled with biocompatible polymer to seal proximally and distally and also occupy the aneurysm flow lumen. This mechanism vs the circumferential radial force of a conventional aortic stent-graft makes EVAS appropriate for treating paravisceral aneurysms. Active endobags filling produces a variable diameter throughout the seal zone compared to the uniform diameter of the proximal stent achieved by the radial force of conventional aortic stent-grafts. This variable diameter of the EVAS endobags may allow better utilization of infrarenal seal zones with poor morphology and obviate the need for a complex endovascular repair. 
	Combining the EVAS technique with chimneys (ChEVAS) to maintain visceral artery perfusion is a novel alternative to FEVAR.15 The active intraoperative filling of the endobags may, in vitro, reduce the occurrence of “gutters” in comparison to ChEVAR.11,16 The Ascend Registry17 and early case series18,19 of ChEVAS have reported encouraging early results. Comparison of these results with those of FEVAR is complicated by the fact both ChEVAS and FEVAR are complex endovascular interventions and as such have limitations associated with anatomical suitability. The goal of this study was to understand how the techniques differ in practice by determining how many EVAS interventions could have been performed in a patient cohort treated using FEVAR.

Methods
Sixty consecutive patients (median age 76.3 years; 54 men) who underwent FEVAR within our institution between May 2013 and October 2015 were selected from our local database. Patients having FEVAR as a secondary intervention for a complication of a previous open or endovascular repair were excluded. Baseline patient data are presented in Table 1. The median aneurysm diameter was 62.0 mm (interquartile range 59.3, 69.0). Table 2 shows the configuration of the FEVAR devices for the cohort.
	The preoperative computed tomography angiography (CTA) scans were retrieved from institutional archives, anonymized, and sent to 2 physicians (S.Z. and R.J.) at an independent German institution. Both of these planning physicians had experience of >40 ChEVAS procedures, which were included in the Ascend Registry.17 The planners, who were blinded to the purpose of the study, were tasked with collectively assessing patient anatomical suitability for a repair using an EVAS technique and to plan the most suitable repair, if deemed possible. These data were collected on a form and returned to the UK institution for analysis. In addition to the planned technical feasibility, the planners also assessed the clinical appropriateness of EVAS in light of the current Nellix IFU.20 

Definitions
A comparison of FEVAR and EVAS requires a definition as to the level at which each technique seals and what constitutes a target vessel. For this study, EVAS techniques were deemed to have a seal zone at the intended upper level of the endobag, and all vessels requiring stenting in ChEVAS are referred to as “chimney vessels.” FEVAR can be described to seal at either the upper extent of the fabric, thereby “including scallops” or at the more distal level where circumferential fabric coverage was achieved (excluding scallops, ie, the upper extent of fabric minus the height of any scallop that does not seal within the entire circumference of the aorta). Both of these definitions were considered when analyzing the FEVAR cohort. “Fenestration vessels” were visceral arteries that were preserved by a fenestration, all of which would be stented. “Target vessels” were any vessel that would be covered if not for a fenestration or a scallop. Scallops are not routinely stented in our institution.

Outcomes
The primary outcome of the study was the percentage of patients technically suitable to undergo EVAS (with or without chimneys) in the FEVAR cohort. Secondary outcomes were differences between proposed EVAS and actual FEVAR seal zones, the number of target vessels, and device costs for FEVAR and the planned EVAS cases.

Statistical Analysis
Data analysis was preplanned and recorded in the study protocol. Patient descriptive data were reported using median values and interquartile ranges in parenthesis for continuous variables and absolute numbers with percentages for categorical variables. The number and percentage of patients in whom EVAS could be performed were reported for the primary outcome, with a description of the cases in which EVAS was not possible. The proposed number of target vessels / fenestration vessels and chimney vessels and the planned landing zones were treated as categorical ordinal variables; the Wilcoxon rank sum test was employed to compare the groups. 
	The current total cost to purchase each endoprosthesis and the visceral stents was reported. The operative notes for the FEVAR procedures in this patient cohort demonstrated that a greater number of visceral stents may be required to secure each target vessel in FEVAR due to individual anatomical variation and surgical complications, eg, dissection. As similar costs could not be calculated for the theoretical EVAS interventions, these extra visceral stents were not included in the cost calculations. Statistical analysis was undertaken using SPSS software (version 22.0; IBM Corporation, Armonk, NY, USA).

Results
An EVAS-based intervention was technically possible and a plan constructed for 56 (93.3%) patients. Four (6.7%) patients were not eligible for EVAS owing to perivisceral thrombus felt likely to embolize into the visceral arteries (2 patients) and no Nellix device of suitable length (2 patients). Despite the planning physicians being blinded to the purpose of the analysis, FEVAR was advocated as more appropriate in 2 of the 4 patients. The planners would not currently advocate EVAS in 43 (76.7%) of the 56 patients due to concerns regarding the risk of migration associated with the lumen thrombus ratios observed in these patients. This is in line with the recently modified IFU of the Nellix device,20 which recommends a “ratio of maximum aortic aneurysm diameter to maximum aortic blood lumen diameter <1.4.”
	The number of grafts stratified by proximal aortic seal zone for both FEVAR and technically feasible EVAS interventions are presented in Figure 1. The proximal aortic seal zones were compared between FEVAR and EVAS in those cases deemed technically possible. When the FEVAR seal zone “excluding scallops” was compared to the planned EVAS intervention, EVAS had a significantly more distal median seal zone (zone 7 vs zone 8, Z=–6.650, p<0.001). This difference was more evident when the FEVAR seal zone “including scallops” was used (zone 6 vs zone 8, Z=–6.650, p<0.001). Infrarenal EVAS was felt to be the most appropriate intervention in 13 (23.2%) patients, but this was outside the IFU for 11 patients.
	The configuration and number of chimney vessels in the EVAS interventions is presented in Table 3. In short, ChEVAS was not possible in 4 (6.7%) patients. Thirteen (21.7%) patients could have had an infrarenal EVAS, and 43 (73.3%) patients could have a ChEVAS planned. There were significantly more fenestration vessels in FEVAR than chimney vessels in EVAS (median 3 vs 2, Z=–5.908, p<0.001). There was a larger difference in the number of FEVAR target vessels and EVAS chimney vessels (median 4 vs 2, Z=–6.618, p<0.001).
	The total reported cost of each procedure was calculated using the individual costs of the standard devices employed in our center. The mean device costs of the FEVAR cases were £14,450, in comparison to the planned EVAS device cost of £9,700. 

Discussion
This study demonstrated that planned EVAS and FEVAR solutions for treating juxtarenal AAAs were significantly different in terms of the proximal seal zone location, visceral vessel involvement, and cost. EVAS interventions had significantly more distal seal zones and correspondingly fewer visceral vessels involved in the repair compared to FEVAR regardless of whether one considers the bottom of the scallop or the top of the fabric as the seal zone in FEVAR.
	While there is limited knowledge of factors that lead to poor outcomes following ChEVAS, in our cohort the majority of the 56 technically feasible EVAS cases were judged to be outside the current infrarenal IFU20 regarding thrombus diameters, which have been recently updated owing to the risk for migration.21 This represents a recent development in EVAS knowledge and as such is a reminder that technical applicability should not be conflated with clinical appropriateness.
	Early results of ChEVAS are encouraging; however, the efficacy of any aneurysm treatment is determined by long-term outcomes. Our findings are particularly important as EVAS investigators start to report aneurysm-related outcomes for complex aneurysm repairs. The natural benchmark for comparison of these complex EVAS interventions is FEVAR outcomes. Using either seal zone or number of visceral vessels as a comparator of aneurysm morphology between treatment modalities is likely to produce heterogeneous groups. As such, investigators are urged to provide a much more detailed description of aneurysm morphology in reports of outcomes to facilitate anatomical matching.
	Given the technical differences between ChEVAS and FEVAR a surprisingly large proportion (93.3%) of patients could have had EVAS. Two of the 4 patients were unsuitable for EVAS because no Nellix device of sufficient length was available. A “Nellix-in-Nellix extension” procedure has been described22 to overcome this but represents another level of complexity on top of a ChEVAS. This study, of course, did not consider patients who were turned down for FEVAR, but given such a high proportion of technical applicability in the considered cohort, it seems likely that EVAS would have been feasible in some patients turned down for FEVAR. The clinical appropriateness of an EVAS intervention in this group would be dependent on the thrombus ratios observed and the risks of other possible endovascular or surgical techniques.

Limitations
The ChEVAS planners may have been influenced by the theoretical nature of planning EVAS procedures compared to the physicians who planned the actual FEVAR procedures. The fact that two different centers produced the plans may have introduced bias regarding differing philosophies toward complex aneurysm repair. However, no one center is likely to have sufficient numbers of ChEVAS and FEVAR cases to produce a meaningful comparison of outcomes. Besides, using planners from a different center did guarantee blinding.
	The cost comparison, which favored the planned EVAS interventions, was influenced in part by the lower number of visceral stents required and the “off-the-shelf” nature of the main Nellix grafts compared to the custom-made FEVAR devices. Device cost has limited value, as it represents only a small component of total implantation costs (which also include operating time and disposables) and total treatment costs (which include inpatient stay and subsequent surveillance/intervention costs).

Conclusion
EVAS-based interventions were technically feasible for the majority of patients in a cohort who were treated with FEVAR for complex aneurysms; however, the planners could not advocate EVAS in more than three-quarters of these technically feasible cases due to high lumen thrombus ratios. The planned EVAS interventions sealed significantly more distally and incorporated significantly fewer visceral vessels than the FEVAR repairs actually performed. Device costs were lower in the planned EVAS interventions, but further cost analysis is required to establish the true total cost of each treatment. 
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Figure 1. Seal zones of planned endovascular aneurysm sealing (EVAS) or chimney EVAS (chEVAS) interventions in a consecutive series of 60 patients treated using fenestrated endovascular aneurysm repair (FEVAR) in a single UK institution. CA, celiac artery; LRA, left renal artery; RRA, right renal artery; SMA; superior mesenteric artery.

Table 1. Preoperative Characteristics of 60 Consecutive Patients Undergoing Fenestrated Endovascular Aneurysm Repair in a Single UK Institution.a
Age, y	76.3 (71.7, 79.7)
Men	54 (90.0)
Diabetes mellitus	12 (20.0 )
Hypertension	38 (63.3)




   Never	10 (16.7)
   Former	42 (70.0)
   Current 	8 (13.3)
CKD stage
   1	2 (3.3)
   2	25 (41.7)
   3a	22 (36.7)
   3b	10 (16.7)
   4	1 (1.7)
ASA grade
   1	1 (1.7)
   2	25 (41.7)
   3	30 (50.0)
   4	1 (1.7)
   Unknown	3 (5.0)
Aneurysm extent
   Infrarenal ≥10-mm neck	21 (35.0)
   Juxtarenal <10-mm neck	26 (43.3)
   Pararenal	11 (18.3)
   Suprarenal extension	2 (3.3)
Abbreviations: ASA, American Society of Anesthesiologists; CKD, chronic kidney disease.
aContinuous data are presented as the median (interquartile range); categorical data are given as the counts (percentage).









2 (3.3)	F	F	F to RRA or LRA	3	
1 (1.7)	S	F	F	2	
Abbreviations: CA, celiac axis; F, fenestration; LRA, left renal artery; RRA, right renal artery; S, scallop; SMA; superior mesenteric artery.









13 (21.7)	Infrarenal EVAS	0 
4 (6.7)	EVAS/ChEVAS not possible
Abbreviations: CA, celiac axis; Ch, chimney; EVAS, endovascular aneurysm sealing; LRA, left renal artery; RRA, right renal artery; SMA; superior mesenteric artery.
 aData are presented as the counts (percentage).






